Innate Pharma Files 6-K, Cites CEO on J.P. Morgan Conference
Ticker: IPHYF · Form: 6-K · Filed: Jan 16, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, conference-update, sec-filing
TL;DR
Innate Pharma 6-K filed Jan 16, 2025. CEO quoted on JPM conference. Standard update.
AI Summary
Innate Pharma S.A. filed a Form 6-K on January 16, 2025, reporting information as of that date. The filing is for a foreign private issuer and indicates that the company files annual reports under Form 20-F. The document includes an incorporation by reference to Exhibit 99.1, which contains a quotation from CEO Johnathan Dickinson regarding the 43rd Annual J.P. Morgan Healthcare Conference.
Why It Matters
This filing provides an update on Innate Pharma's reporting status and references a key executive's commentary on a significant industry event, offering insight into the company's engagement with investors and the broader healthcare landscape.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as an update and incorporation by reference, with no immediate material financial events disclosed.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- Johnathan Dickinson (person) — Chief Executive Officer and Chairman of the Executive Board
- 43rd Annual J.P. Morgan Healthcare Conference (event) — Mentioned in filing
- January 16, 2025 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing by Innate Pharma S.A.?
The primary purpose is to report information as a foreign private issuer and to incorporate by reference Exhibit 99.1, which includes a statement from the CEO regarding the 43rd Annual J.P. Morgan Healthcare Conference.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on January 16, 2025.
Does Innate Pharma S.A. file annual reports under Form 20-F or Form 40-F?
Innate Pharma S.A. files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.
Who is quoted in the incorporated Exhibit 99.1?
Johnathan Dickinson, Chief Executive Officer and Chairman of the Executive Board of Innate Pharma S.A., is quoted in the incorporated Exhibit 99.1.
What specific event is mentioned in relation to the CEO's quote?
The CEO's quote is related to the 43rd Annual J.P. Morgan Healthcare Conference.
Filing Stats: 284 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2025-01-16 08:16:18
Filing Documents
- a6k-iphx250116.htm (6-K) — 11KB
- exhibit991-2501101.htm (EX-99.1) — 19KB
- 0001598599-25-000004.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date January 16, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chairman of the Executive Board and Chief Executive Officer